ArticleDalton transactions (Cambridge, England : 2003)2013
Characterization of a versatile organometallic pro-drug (CORM) for experimental CO based therapeutics.
Article in Dalton transactions (Cambridge, England : 2003), 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed.
- Carbon monoxide-releasing molecule CORM-401 treatment elicits corticosterone-driven stress lipolysis and tissue-specific hypoxia-inducible factor activation.Redox biology · 2026Article
- Oral Delivery Systems for Gasotransmitters in Therapeutic Applications.Polymer science & technology (Washington, D.C.) · 2026Review
- Metal-Free CO Prodrugs Activated by Molecular Oxygen Protect against Doxorubicin-Induced Cardiomyopathy in Mice.Journal of medicinal chemistry · 2024Article
- Fluorescent small molecule donors.Chemical Society reviews · 2024Review
- Carboxyhemoglobin (COHb): Unavoidable Bystander or Protective Player?Antioxidants (Basel, Switzerland) · 2023Review
- Tricarbonyl-Pyrazine-Molybdenum(0) Metal-Organic Frameworks for the Storage and Delivery of Biologically Active Carbon Monoxide.ACS biomaterials science & engineering · 2023Article
- Synergetic Antimicrobial Activity and Mechanism of Clotrimazole-Linked CO-Releasing Molecules.ACS bio & med chem Au · 2022Article
- Hydrophilic CO-Releasing Material of PEGlyated Ruthenium Carbonyl Complex.Materials (Basel, Switzerland) · 2022Article
- "CO in a pill": Towards oral delivery of carbon monoxide for therapeutic applications.Journal of controlled release : official journal of the Controlled Release Society · 2021Review
- The potentials of carbon monoxide-releasing molecules in cancer treatment: An outlook from ROS biology and medicine.Redox biology · 2021Review
- Phototriggered cytotoxic properties of tricarbonyl manganese(I) complexes bearing α-diimine ligands towards HepG2.Journal of biological inorganic chemistry : JBIC : a publication of the Society of Biological Inorganic Chemistry · 2021Article
- Carbon Monoxide as a Therapeutic for Airway Diseases: Contrast and Comparison of Various CO Delivery Modalities.Current topics in medicinal chemistry · 2021Review
- CO-Releasing Materials: An Emphasis on Therapeutic Implications, as Release and Subsequent Cytotoxicity Are the Part of Therapy.Materials (Basel, Switzerland) · 2019Review
- Article
- Article
- Neuroprotection and neuroregeneration of retinal ganglion cells after intravitreal carbon monoxide release.PloS one · 2017Article
- The use of polyoxometalates in protein crystallography - An attempt to widen a well-known bottleneck.Coordination chemistry reviews · 2015Review
- CO-releasing Metal Carbonyl Compounds as Antimicrobial Agents in the Post-antibiotic Era.The Journal of biological chemistry · 2015Review
- Novel lead structures and activation mechanisms for CO-releasing molecules (CORMs).British journal of pharmacology · 2015Review
- Carbon monoxide--physiology, detection and controlled release.Chemical communications (Cambridge, England) · 2014Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors.
Funding
Abstract
The complex fac-[Mo(CO)(3)(histidinate)]Na has been reported to be an effective CO-Releasing Molecule in vivo, eliciting therapeutic effects in several animal models of disease. The CO releasing profile of this complex in different settings both in vitro and in vivo reveals that the compound can readily liberate all of its three CO equivalents under biological conditions. The compound has low toxicity and cytotoxicity and is not hemolytic. CO release is accompanied by a decrease in arterial blood pressure following administration in vivo. We studied its behavior in solution and upon the interaction with proteins. Reactive oxygen species (ROS) generation upon exposure to air and polyoxomolybdate formation in soaks with lysozyme crystals were observed as processes ensuing from the decomposition of the complex and the release of CO.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.